Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under NASDAQ Listing Rule 5635(c)(4) to six new employees for an aggregate of 20,000 shares.
The options were granted on March 13, 2026 at an exercise price of $13.20 (closing price that day), have a 10-year term and vest over four years (25% after one year, then monthly).
EyePoint (Nasdaq: EYPT) reported Q4 and full-year 2025 results and corporate updates on March 4, 2026. Key clinical milestones: Phase 3 wet AMD topline readouts begin mid-2026; DME Phase 3 topline data expected H2 2027. Financials: $306 million cash and investments at year-end, runway into Q4 2027; FY 2025 net revenue $31.4M versus $43.3M prior year; FY 2025 net loss $232.0M (GAAP). Corporate: appointed CCO Michael Campbell, issued U.S. patent extending DURAVYU coverage to 2043, completed $172.5M offering and finished registration manufacturing batches for NDA support.
EyePoint (Nasdaq: EYPT) announced first patients dosed in two global Phase 3 trials (COMO and CAPRI) of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema (DME) on March 2, 2026. Each randomized, aflibercept-controlled non-inferiority trial will enroll ~240 patients with DURAVYU 2.7mg re-dosed every six months.
Key points: topline DME data anticipated in 2H 2027; primary endpoint is non-inferior change in BCVA at weeks 52 and 56; secondary endpoints include safety, treatment burden reduction, supplemental aflibercept use, and OCT anatomy. Program aligned with FDA and EMA.
EyePoint (Nasdaq: EYPT) will report fourth-quarter and full-year 2025 results and host a conference call and live webcast at 8:30 a.m. ET on March 4, 2026. The event will include a review of financial results and recent corporate developments.
According to the company, registration is required for the audio conference and a live webcast plus replay will be available on the company's investor website.
EyePoint (Nasdaq: EYPT) said management will participate in four investor events in March 2026: TD Cowen (March 3), Barclays (March 10), Jefferies Biotech on the Beach (March 11) and RBC Virtual Ophthalmology (March 25).
A live webcast and archived replay will be available via the company’s Investors website.
EyePoint (Nasdaq: EYPT) appointed Michael Campbell as Chief Commercial Officer effective Feb 18, 2026. Mr. Campbell brings over 30 years of commercial leadership in retinal disease and will lead commercial strategy and launch readiness for DURAVYU (vorolanib intravitreal insert), currently in Phase 3.
The company granted an inducement award of 175,000 stock options with a four-year vesting schedule; options use the Feb 17, 2026 closing price as the exercise price.
EyePoint (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under Nasdaq Listing Rule 5635(c)(4) to six new employees totaling 143,000 shares.
The options were granted on February 13, 2026, at an exercise price of $12.94 (closing price that day), have a 10-year term, and vest over four years (25% after one year, then monthly).
EyePoint (Nasdaq: EYPT) announced that George O. Elston, EVP and CFO, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 AM ET. A live webcast and archived replay will be available via the company Investors website at www.eyepoint.bio.
EyePoint (Nasdaq: EYPT) granted non-statutory inducement stock options to three new employees to purchase an aggregate of 13,900 shares of common stock. The options were granted on January 15, 2026 with an exercise price of $15.84 per share (the January 15 closing price), a 10-year term, and vesting over 4 years (25% after one year, then monthly over three years). Grants were approved by the Compensation Committee and made under NASDAQ Listing Rule 5635(c)(4) as inducement awards, with vesting conditioned on continued service.
EyePoint (Nasdaq: EYPT) provided a corporate update outlining pivotal 2026 milestones for DURAVYU (vorolanib intravitreal insert).
Key points: completed enrollment of >900 patients across Phase 3 LUGANO (432 U.S. patients) and LUCIA (475 global patients); topline wet AMD Phase 3 data expected beginning in mid-2026; Phase 3 DME trials COMO and CAPRI plan first patient dosing in Q1 2026 (~240 patients each); DURAVYU registration batches are in production to support an expedited NDA; corporate cash of approximately $300M at Dec 31, 2025 and a completed public offering raising $172.5M, providing runway into Q4 2027.